SU2C forms three teams focused on treatments for lung cancer and Ewing sarcoma

Pasi Jänne receives 2024 Bonnie J. Addario Lectureship Award

Pasi A. Jänne received the GO2 for Lung Cancer’s 2024 Bonnie J. Addario Lectureship Award.

August 02, 2024

Vaping and smoking together increases lung cancer risk fourfold

People who both vape and smoke are four times more likely to develop lung cancer than people who just smoke, according to a new study published by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and College of Public Health.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Ninety-three percent of oncologists adjust treatment recommendations with OncoHost’s PROphetNSCLC test

OncoHost, a technology company, announced the publication of a study in Clinical Lung Cancer demonstrating the impact of its PROphetNSCLC test on first-line treatment decisions for metastatic non-small cell lung cancer patients.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Neighborhood violence may influence tumor biology, worsening lung cancer outcomes

Scientists have identified a potential driver of aggressive lung cancer tumors in patients who live in areas with high levels of violent crime. Their study found that stress responses differ between those living in neighborhoods with higher and lower levels of violent crime, and between cancerous and healthy tissues in the same individuals.

July 26, 2024

Vol.50 No.30

Cancer History Project

“If I’m not dying, I better go live.” Christy Erickson’s cancer diagnosis led to life as a motorcyclist and strongman competitor

Christy Erickson was seven years old when her mom lost a three-year battle with breast cancer.

July 12, 2024

Vol.50 No.28

By McKenzie Prillaman

Cancer History Project Guest Editorial

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

July 05, 2024

Vol.50 No.27

By Katerina A. Politi and Roy S. Herbst

SU2C forms three teams focused on treatments for lung cancer and Ewing sarcoma

YOU MAY BE INTERESTED IN

Pasi Jänne receives 2024 Bonnie J. Addario Lectureship Award

Vaping and smoking together increases lung cancer risk fourfold

Ninety-three percent of oncologists adjust treatment recommendations with OncoHost’s PROphetNSCLC test

Neighborhood violence may influence tumor biology, worsening lung cancer outcomes

“If I’m not dying, I better go live.” Christy Erickson’s cancer diagnosis led to life as a motorcyclist and strongman competitor

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

Renew today!

Subscriber content

Login